Anavex Life Sciences’ (AVXL) “Buy” Rating Reiterated at D. Boral Capital

D. Boral Capital reissued their buy rating on shares of Anavex Life Sciences (NASDAQ:AVXL) in a research note published on Tuesday morning,Benzinga reports. D. Boral Capital currently has a $24.00 price objective on the biotechnology company’s stock.

Other research analysts also recently issued research reports about the stock. Wall Street Zen raised shares of Anavex Life Sciences from a “sell” rating to a “hold” rating in a report on Saturday, February 14th. HC Wainwright reaffirmed a “buy” rating and issued a $20.00 target price on shares of Anavex Life Sciences in a report on Tuesday, February 10th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Anavex Life Sciences in a research report on Monday, December 29th. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $22.00.

Anavex Life Sciences Price Performance

Anavex Life Sciences stock opened at $2.99 on Tuesday. Anavex Life Sciences has a 1 year low of $2.61 and a 1 year high of $13.99. The firm’s 50 day moving average price is $4.21 and its 200-day moving average price is $5.46. The stock has a market cap of $277.08 million, a P/E ratio of -6.50 and a beta of 1.18.

Anavex Life Sciences (NASDAQ:AVXL) last issued its earnings results on Monday, February 9th. The biotechnology company reported ($0.06) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.10) by $0.04. As a group, equities analysts expect that Anavex Life Sciences will post -0.69 EPS for the current year.

Institutional Trading of Anavex Life Sciences

Several institutional investors have recently added to or reduced their stakes in AVXL. State of Wyoming bought a new position in shares of Anavex Life Sciences during the second quarter valued at approximately $26,000. AlphaQuest LLC bought a new stake in shares of Anavex Life Sciences during the 3rd quarter worth approximately $29,000. Quarry LP bought a new stake in shares of Anavex Life Sciences during the 3rd quarter worth approximately $36,000. HBW Advisory Services LLC purchased a new position in Anavex Life Sciences during the 4th quarter valued at $40,000. Finally, BNC Wealth Management LLC boosted its holdings in Anavex Life Sciences by 19.5% during the 4th quarter. BNC Wealth Management LLC now owns 12,250 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 2,000 shares during the period. Institutional investors own 31.55% of the company’s stock.

About Anavex Life Sciences

Anavex Life Sciences Corp is a clinical‐stage biopharmaceutical company focused on the development of novel therapeutics for central nervous system (CNS) disorders. The company applies a proprietary drug discovery platform that targets sigma‐1 and muscarinic receptors to modulate cellular stress pathways and support neuronal function. Headquartered in New York City, Anavex is dedicated to advancing treatments for neurodegenerative and neurodevelopmental diseases with high unmet medical need.

The company’s lead product candidate, blarcamesine (ANAVEX2‐73), is a small‐molecule activator of the sigma‐1 receptor currently being evaluated in clinical trials for Alzheimer’s disease and Parkinson’s disease dementia.